| Prev Close | 18.78 |
| Open | 18.90 |
| Day Low/High | 18.55 / 19.04 |
| 52 Wk Low/High | 7.35 / 14.35 |
| Volume | 524.01K |
| Avg Volume | 1.16M |
| Exchange | NASDAQ |
| Shares Outstanding | 148.62M |
| Market Cap | 2.79B |
| EPS | -0.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Ironwood Pharmaceuticals To Present At The Jefferies Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies Healthcare Conference on Thursday, June 8, 2017 at 4:00 p.
Ironwood Pharmaceuticals To Present At The Bank Of America Merrill Lynch Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 17, 2017 at 1:00 p.
Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect On Pain At Digestive Disease Week® 2017
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, this week presented clinical data on the effect of linaclotide on abdominal pain in irritable bowel syndrome with constipation (IBS-C)...
Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, today provided an update on its first quarter 2017 results and recent business activities.
Ironwood Pharmaceuticals To Present New Data For Linaclotide, Linaclotide Delayed Release And IW-1701 At Digestive Disease Week® 2017
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company and its collaborators will present clinical and preclinical data for linaclotide and linaclotide...
First Week of IRWD June 16th Options Trading
Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the June 16th expiration.
Ironwood Pharmaceuticals To Host First Quarter 2017 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2017 investor update conference call and webcast at 8:30 a.
Ironwood Pharmaceuticals Appoints Dr. Christopher Wright As Senior Vice President Of Global Development And Chief Development Officer
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the appointment of Christopher Wright, M.
Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 16, 2017 at 10:45 a.
Ironwood Pharmaceuticals Showcases Progress Delivering Innovative Medicines To Patients And Building A Top-Performing Commercial Biotech At R&D Day 2017
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, is hosting an R&D Day today, Thursday, March 9, 2017, beginning at 9:00 a.
Ironwood Pharmaceuticals To Present At Cowen And Company 37th Annual Health Care Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Cowen and Company 37 th Annual Health Care Conference on Monday, March 6, 2017 at 2:00 p.
Ironwood Pharmaceuticals To Host R&D Day On March 9, 2017
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will host a live webcast of its R&D Day on Thursday, March 9, 2017 beginning at 9:00 a.
Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2016 Investor Update
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2016 results and recent business activities.
5 Ways Allergan Can Keep Up Momentum
Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.
Ironwood Pharmaceuticals Reaches Analyst Target Price
In recent trading, shares of Ironwood Pharmaceuticals Inc. have crossed above the average analyst 12-month target price of $16.25, changing hands for $16.38/share.
Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2016 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2016 investor update conference call and webcast at 4:30 p.
Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday.
Astellas And Ironwood Report Positive Top-Line Results From Phase III Linaclotide Trial For Patients With Chronic Constipation Conducted In Japan
Astellas Pharma Inc. (TSE:4503) and Ironwood Pharmaceuticals, Inc.
Synergy Pharmaceuticals Secures Approval for Linzess Competitor
New bowel drug Trulance will be available for patients later this quarter.
Ironwood Pharmaceuticals Demonstrates Strong Execution On Strategy To Build Top-Performing Commercial Biotech
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today detailed strong execution against its strategy of building a top-performing commercial biotechnology company generating rapid, sustainable, high-margin growth.
Ironwood Pharmaceuticals Appoints Amy Schulman To Board Of Directors
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the appointment of Amy Schulman to its board of directors.
Ironwood Announces New Drug Application For DUZALLO™ (Fixed-Dose Combination Of Lesinurad And Allopurinol) Has Been Accepted For FDA Review
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the U.
Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 35 th Annual J.
Ironwood And Allergan Report Topline Phase IIb Data Supporting Advancement Of Linaclotide Colonic Release-1 (CR1) In IBS-C
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) announced today positive topline data from a Phase IIb clinical trial evaluating the investigational linaclotide colonic release-1...
Ironwood And Allergan Report Topline Phase IIb Data Supporting Further Investigation Of Linaclotide Colonic Release-2 (CR2) For Abdominal Pain In Non-Constipation Subtypes Of IBS
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) announced today topline data from a Phase IIb clinical trial evaluating an investigational linaclotide colonic release-2 (CR2)...
Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In Japan For The Treatment Of Adults With IBS-C
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that its partner, Astellas Pharma Inc.
Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data At The American College Of Rheumatology 2016 Annual Meeting
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today presented efficacy and safety data from two Phase III extension studies of ZURAMPIC (lesinurad), as well as pooled analyses from the two extension studies and...
Ironwood Pharmaceuticals To Present At Stifel 2016 Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Stifel 2016 Healthcare Conference on Wednesday, November 16th, 2016 at 8:00 a.
